ganciclovir "oresund pharma" 500 mg pulver til koncentrat til infusionsvæske, opløsning
Øresund pharma aps - ganciclovirnatrium - pulver til koncentrat til infusionsvæske, opløsning - 500 mg
clopidogrel acino pharma gmbh
acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
lamivudine teva pharma b.v.
teva b.v. - lamivudin - hiv infektioner - antivirale midler til systemisk anvendelse - lamivudin teva pharma b. indikeres som en del af antiretroviral kombinationsbehandling til behandling af humane immunsvigt-virus (hiv) -inficerede voksne og børn.
budesonid "europharma" 200 mikrogram/dosis inhalationspulver
europharma.dk aps - budesonid - inhalationspulver - 200 mikrogram/dosis
budesonid "europharma" 400 mikrogram/dosis inhalationspulver
europharma.dk aps - budesonid - inhalationspulver - 400 mikrogram/dosis
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
ribavirin teva pharma b.v.
teva b.v. - ribavirin - hepatitis c kronisk - antivirale midler til systemisk anvendelse - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 og 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 og 5.
pregabalin mylan pharma
mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptika, - epilepsypregabalin mylan pharma er indiceret som adjuverende behandling til voksne med partielle anfald med eller uden sekundær generalisering. generaliseret angst disorderpregabalin mylan pharma er indiceret til behandling af generaliseret angst (gad) hos voksne.
budesonide "teva pharma" 0,25 mg/ml inhalationsvæske til nebulisator, suspension
teva pharma b.v. - budesonid - inhalationsvæske til nebulisator, suspension - 0,25 mg/ml